Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089076 · ClinicalTrials.gov registry record · Phase 1
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00089076: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00089076 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089076, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop cancer cells from growing. This phase I/II trial is studying the side effects and best dose of MDX-010 and to see how well it works in treating patients with recurrent or refractory B-cell non-Hodgkin's lymphoma.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089076
The ClinicalTrials.gov registry entry for NCT00089076 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00089076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089076 about?
NCT00089076 is a clinical study titled "MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma". Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop cancer cells from growing. This phase I/II trial is studying the side effects and best dose of MDX-010 and to see how well it works in treating patients with recurrent or refractory B-cell non-Hodgk...
What is the current status of trial NCT00089076?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2004-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00089076?
The interventions under investigation include: laboratory biomarker analysis (OTHER), ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00089076?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.